We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

126 hedge funds and large institutions have $249M invested in CytomX Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.45% more ownership

Funds ownership: 79.76% → 82.21% (+2.4%)

2% more capital invested

Capital invested by funds: $243M → $249M (+$5.62M)

3% less funds holding

Funds holding: 130 → 126 (-4)

16% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 51

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
126
Holders Change
-4
Holders Change %
-3.08%
% of All Funds
2.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
43
Reduced
51
Closed
15
Calls
$88K
Puts
–
Net Calls
+$88K
Net Calls Change
+$22K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$14.4M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$2.46M
3
Morgan Stanley
Morgan Stanley
New York
+$2.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.58M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$2.3M
2
BlackRock
BlackRock
New York
-$2.15M
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$1.85M
4
Norges Bank
Norges Bank
Norway
-$1.76M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Manhattan
126
First Manhattan
New York
– -$2.3M -345,451 Closed
Norges Bank
127
Norges Bank
Norway
– -$1.76M -265,000 Closed
AG
128
Artal Group
Luxembourg
– -$1.19M -178,600 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
129
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$835K -125,500 Closed
TCM
130
Tang Capital Management
California
– -$751K -112,880 Closed
MAM
131
Martingale Asset Management
Massachusetts
– -$662K -99,423 Closed
AL
132
AJO LP
Pennsylvania
– -$443K -66,641 Closed
EGM
133
Engineers Gate Manager
New York
– -$189K -28,409 Closed
SG Americas Securities
134
SG Americas Securities
New York
– -$145K -21,797 Closed
DTL
135
Dynamic Technology Lab
Singapore
– -$117K -17,660 Closed
DT
136
Diversified Trust
Tennessee
– -$91K -13,651 Closed
HS
137
HighVista Strategies
Massachusetts
– -$86K -13,000 Closed
PCM
138
Prelude Capital Management
New York
– -$11K -1,700 Closed
GT
139
Glenmede Trust
Pennsylvania
– -$7K -1,076 Closed
IA
140
IFP Advisors
Florida
– -$557 -78 Closed
IA
141
Inspire Advisors
Idaho
– +$536 +75 New
2 3 4 5
6

CTMX Hedge Fund Activity: Q4 2020 in Review

126 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2020, worth a combined $249M — up 2.3% from $243M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CTMX and 11 opened new positions — a net loss of 4 holders — while 51 trimmed existing stakes and 43 added.

The largest buyer was BVF Inc, adding an estimated $14.4M. The largest seller was First Manhattan, exiting entirely with an estimated $2.3M sold.

  • 126 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2020, down from 130 in Q3 2020.
  • Funds reported $249M of CytomX Therapeutics stock for Q4 2020, up 2.3% quarter-over-quarter.
  • 11 funds opened new CytomX Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
  • The largest CytomX Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14.4M added.
  • The largest CytomX Therapeutics seller in Q4 2020 was First Manhattan, an estimated $2.3M sold.

Based on aggregated 13F filings for Q4 2020.